Tiagabine.
Pierce
M W
MW
Abbott Laboratories, Abbott Park, IL.
Suzdak
P D
PD
Gustavson
L E
LE
Mengel
H B
HB
McKelvy
J F
JF
Mant
T
T
D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects; D015507:Drugs, Investigational / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004569:Electroencephalography / Q000187:drug effects; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D005071:Evoked Potentials / Q000187:drug effects; D006801:Humans; D051379:Mice; D009557:Nipecotic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051381:Rats; D000078308:Tiagabine
D000927:Anticonvulsants; D015507:Drugs, Investigational; D009557:Nipecotic Acids; D000078308:Tiagabine